IGM Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Cash & Equivalents	113.11	121.92	134.04	241.08	35.89	1.99	0.48
Short-Term Investments	225.16	305.93	96.21	125.19	188.74	0	0
Cash & Cash Equivalents	338.27	427.85	230.24	366.27	224.63	1.99	0.48
Cash Growth	-20.94%	85.83%	-37.14%	63.05%	11205.18%	312.24%	-
Receivables	0	0	0	0	0	-2.51	-34.63
Other Current Assets	9.33	10.57	10.5	7	6.47	2.93	34.8
Total Current Assets	347.6	438.42	240.75	373.27	231.1	2.41	0.66
Property, Plant & Equipment	74.01	73.08	56.34	34.81	18.02	1.47	0.68
Long-Term Investments	0	0	0	0	11.97	0	0
Other Long-Term Assets	1.81	2	1.04	0.55	0.26	0.1	0.06
Total Long-Term Assets	75.81	75.08	57.38	35.36	30.25	1.57	0.74
Total Assets	423.41	513.5	298.13	408.63	261.35	3.98	1.39
Accounts Payable	1.33	2.51	5.58	7.92	3.09	0.16	0.23
Deferred Revenue	146.8	148.93	0	0	0	0	0
Current Debt	5.83	5.82	3.32	2.67	2.48	5.03	0
Other Current Liabilities	-111.48	-112.57	18.88	6.65	3.31	3.7	0.75
Total Current Liabilities	42.48	44.69	27.78	17.24	8.88	8.89	0.98
Long-Term Debt	34.67	35.36	25.44	9.58	12.24	0	0
Other Long-Term Liabilities	143.02	146.2	0	0	0	0	0.13
Total Long-Term Liabilities	177.7	181.55	25.44	9.58	12.24	0	0.13
Total Liabilities	220.18	226.24	53.22	26.82	21.12	8.89	1.11
Total Debt	40.51	41.17	28.76	12.24	14.73	5.03	0
Debt Growth	-1.62%	43.16%	134.88%	-16.86%	192.96%	-	-
Retained Earnings	-821.24	-574.83	-353.72	-188.56	-107.21	-64.07	-41.36
Comprehensive Income	0.15	-0.7	-0.07	0.03	0.04	0	0
Shareholders' Equity	203.23	287.26	244.91	381.82	240.23	-65.83	-40.5
Net Cash / Debt	297.76	386.68	201.48	354.03	209.91	-3.04	0.48
Net Cash / Debt Growth	-22.99%	91.92%	-43.09%	68.66%	-	-	-
Net Cash Per Share	5.69	9.31	6.02	11.51	23.33	-6.94	1.10
Working Capital	305.12	393.74	212.97	356.03	222.23	-6.48	-0.32
Book Value Per Share	3.88	6.92	7.32	12.42	26.71	-150.27	-92.48

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).